Lasa Supergenerics Limited (LASA.NS)
INR 17.1
(0.06%)
INR 17.1
(0.06%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 1.04 Billion INR | -19.47% |
| 2022 | 1.29 Billion INR | -5.51% |
| 2021 | 1.37 Billion INR | -32.24% |
| 2020 | 2.02 Billion INR | 21.0% |
| 2019 | 1.67 Billion INR | -1.37% |
| 2018 | 1.69 Billion INR | -30.37% |
| 2017 | 2.43 Billion INR | 21.97% |
| 2016 | 1.99 Billion INR | 0.0% |
| 2015 | - INR | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q1 | 308.35 Million INR | 35.15% |
| 2023 Q4 | 228.16 Million INR | -14.42% |
| 2023 FY | 1.04 Billion INR | -19.47% |
| 2023 Q1 | 305.56 Million INR | -13.5% |
| 2023 Q3 | 266.6 Million INR | 9.7% |
| 2023 Q2 | 243.02 Million INR | -20.47% |
| 2022 Q3 | 317.04 Million INR | -5.81% |
| 2022 Q1 | 288.78 Million INR | -43.61% |
| 2022 FY | 1.29 Billion INR | -5.51% |
| 2022 Q4 | 353.22 Million INR | 11.41% |
| 2022 Q2 | 336.61 Million INR | 16.56% |
| 2021 Q1 | 360.66 Million INR | -7.76% |
| 2021 FY | 1.37 Billion INR | -32.24% |
| 2021 Q4 | 512.12 Million INR | 225.42% |
| 2021 Q3 | 157.37 Million INR | -53.86% |
| 2021 Q2 | 341.1 Million INR | -5.42% |
| 2020 Q3 | 539.87 Million INR | -1.29% |
| 2020 Q4 | 391.01 Million INR | -27.57% |
| 2020 FY | 2.02 Billion INR | 21.0% |
| 2020 Q1 | 545.99 Million INR | 12.41% |
| 2020 Q2 | 546.9 Million INR | 0.17% |
| 2019 FY | 1.67 Billion INR | -1.37% |
| 2019 Q4 | 485.71 Million INR | 23.62% |
| 2019 Q3 | 392.89 Million INR | -2.78% |
| 2019 Q2 | 404.11 Million INR | 3.66% |
| 2019 Q1 | 389.84 Million INR | -7.23% |
| 2018 Q3 | 538.83 Million INR | 32.25% |
| 2018 Q2 | 407.44 Million INR | 23.77% |
| 2018 Q1 | 329.2 Million INR | -44.5% |
| 2018 FY | 1.69 Billion INR | -30.37% |
| 2018 Q4 | 420.23 Million INR | -22.01% |
| 2017 FY | 2.43 Billion INR | 21.97% |
| 2017 Q1 | 589.55 Million INR | 0.0% |
| 2017 Q4 | 593.11 Million INR | -2.75% |
| 2017 Q2 | 645.3 Million INR | 9.46% |
| 2017 Q3 | 609.86 Million INR | -5.49% |
| 2016 Q1 | 401.69 Million INR | 0.0% |
| 2016 FY | 1.99 Billion INR | 0.0% |
| 2015 FY | - INR | 0.0% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| Amrutanjan Health Care Limited | 4.21 Billion INR | 75.231% |
| Biofil Chemicals and Pharmaceuticals Limited | 400.35 Million INR | -160.608% |
| Caplin Point Laboratories Limited | 16.76 Billion INR | 93.778% |
| FDC Limited | 19.42 Billion INR | 94.63% |
| Gufic Biosciences Limited | 8.06 Billion INR | 87.066% |
| Hikal Limited | 17.84 Billion INR | 94.154% |
| Ind-Swift Laboratories Limited | 12.8 Billion INR | 91.855% |
| IOL Chemicals and Pharmaceuticals Limited | 21.32 Billion INR | 95.108% |
| Kilitch Drugs (India) Limited | 1.54 Billion INR | 32.413% |
| Medico Remedies Limited | 1.44 Billion INR | 28.005% |
| Nectar Lifesciences Limited | 16.84 Billion INR | 93.806% |
| Par Drugs and Chemicals Limited | 956.4 Million INR | -9.091% |
| RPG Life Sciences Limited | 5.82 Billion INR | 82.075% |
| Sequent Scientific Limited | 13.69 Billion INR | 92.383% |
| Shilpa Medicare Limited | 11.53 Billion INR | 90.952% |
| Sigachi Industries Limited | 3.98 Billion INR | 73.848% |
| Themis Medicare Limited | 3.81 Billion INR | 72.67% |
| Unichem Laboratories Limited | 16.57 Billion INR | 93.705% |
| Venus Remedies Limited | 5.91 Billion INR | 82.359% |
| Wanbury Limited | 5.75 Billion INR | 81.875% |
| ZIM Laboratories Limited | 3.67 Billion INR | 71.611% |
| Lupin Limited | 196.56 Billion INR | 99.469% |
| Innova Captab Limited | 10.81 Billion INR | 90.351% |
| Ind-Swift Limited | 5.02 Billion INR | 79.235% |
| Bajaj HealthCare Limited | 4.73 Billion INR | 77.961% |
| Aurobindo Pharma Limited | 290.01 Billion INR | 99.64% |
| Solara Active Pharma Sciences Limited | 12.38 Billion INR | 91.575% |
| AstraZeneca Pharma India Limited | 12.95 Billion INR | 91.947% |
| Mangalam Drugs & Organics Limited | 3.67 Billion INR | 71.598% |
| Morepen Laboratories Limited | 17.01 Billion INR | 93.869% |
| Laurus Labs Limited | 50.01 Billion INR | 97.914% |
| Aarti Drugs Limited | 25.28 Billion INR | 95.874% |
| Glenmark Life Sciences Limited | 22.83 Billion INR | 95.43% |
| Alembic Limited | 1.57 Billion INR | 33.749% |
| Alembic Pharmaceuticals Limited | 61.12 Billion INR | 98.293% |
| Glenmark Pharmaceuticals Limited | 118.13 Billion INR | 99.117% |
| Vaishali Pharma Limited | 862.79 Million INR | -20.926% |
| Aarti Pharmalabs Limited | 18.15 Billion INR | 94.253% |
| Jagsonpal Pharmaceuticals Limited | 2.08 Billion INR | 50.008% |
| Jubilant Pharmova Limited | 67.02 Billion INR | 98.443% |
| Eris Lifesciences Limited | 20.09 Billion INR | 94.807% |
| Windlas Biotech Limited | 6.3 Billion INR | 83.464% |
| Sun Pharmaceutical Industries Limited | 484.96 Billion INR | 99.785% |
| Lincoln Pharmaceuticals Limited | 5.8 Billion INR | 82.028% |
| Orchid Pharma Limited | 8.19 Billion INR | 87.266% |
| Albert David Limited | 3.62 Billion INR | 71.215% |
| Hester Biosciences Limited | 3.04 Billion INR | 65.741% |
| Sakar Healthcare Limited | 1.54 Billion INR | 32.324% |
| Suven Pharmaceuticals Limited | 10.51 Billion INR | 90.076% |
| Procter & Gamble Health Limited | 11.51 Billion INR | 90.937% |
| Divi's Laboratories Limited | 78.45 Billion INR | 98.67% |
| Mankind Pharma Limited | 103.34 Billion INR | 98.99% |
| Neuland Laboratories Limited | 15.58 Billion INR | 93.306% |
| J. B. Chemicals & Pharmaceuticals Limited | 34.47 Billion INR | 96.974% |
| Zydus Lifesciences Limited | 190.21 Billion INR | 99.451% |
| Wockhardt Limited | 27.89 Billion INR | 96.259% |
| Bal Pharma Limited | 3.39 Billion INR | 69.243% |
| Dr. Reddy's Laboratories Limited | 279.16 Billion INR | 99.626% |
| Bliss GVS Pharma Limited | 7.7 Billion INR | 86.454% |
| Alkem Laboratories Limited | 126.67 Billion INR | 99.176% |
| Valiant Laboratories Limited | 1.82 Billion INR | 42.691% |
| Ajanta Pharma Limited | 42.08 Billion INR | 97.521% |
| Bafna Pharmaceuticals Limited | 1.52 Billion INR | 31.568% |
| Aarey Drugs & Pharmaceuticals Limited | 3.95 Billion INR | 73.627% |
| Granules India Limited | 45.06 Billion INR | 97.685% |
| Medicamen Biotech Limited | 1.79 Billion INR | 41.812% |
| Ipca Laboratories Limited | 77.05 Billion INR | 98.646% |
| Brooks Laboratories Limited | 794.86 Million INR | -31.262% |
| Syncom Formulations (India) Limited | 2.59 Billion INR | 59.754% |
| Piramal Enterprises Limited | 60.33 Billion INR | 98.271% |
| Torrent Pharmaceuticals Limited | 106.05 Billion INR | 99.016% |
| NATCO Pharma Limited | 40.02 Billion INR | 97.393% |
| Suven Life Sciences Limited | 116.92 Million INR | -792.294% |
| Krebs Biochemicals & Industries Limited | 504.21 Million INR | -106.926% |
| Strides Pharma Science Limited | 40.51 Billion INR | 97.425% |
| Indoco Remedies Limited | 18.17 Billion INR | 94.259% |
| Alpa Laboratories Limited | 1.08 Billion INR | 4.05% |
| Sun Pharma Advanced Research Company Limited | 755.45 Million INR | -38.109% |